MAPK1 and heart failure: A clinical trial for semapimod, an anti-inflammatory agent which inhibits p38 activity, was started for heart failure patients, but was apparently terminated upon the disclosure of the discouraging results of the TNF-α-targeted clinical trials (Kerkela and Force, 2006).